In an attempt to expand its neurology pipeline, Roche has signed an agreement with Ascidian Therapeutics to develop RNA exon editing therapeutics for the treatment of neurological diseases. The deal, which could be worth up to US$1.82 B combines Ascidian’s RNA exon editing platform with Roche’s commercialisation expertise, clinical development capabilities, and global distribution network. The deal comes after Ascidian’s drug ACDN-01, the first-ever clinical-stage RNA exon editor, received FDA approval for its clinical development in Stargardt disease.